We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

17 Jun 2026 - 19 Jun 2026
08 Jul 2026 - 10 Jul 2026

Respiratory Panel Evaluated for Acute Respiratory Tract Infections

By LabMedica International staff writers
Posted on 07 Nov 2018
Upper respiratory tract infections (URTI) are illnesses caused by an acute infection that involves the upper respiratory tract including the nose, sinuses, pharynx or larynx. More...
This commonly includes nasal obstruction, sore throat, tonsillitis, pharyngitis, laryngitis, sinusitis, otitis media, and the common cold.

Most infections are viral in nature and in other instances the cause is bacterial. The viruses do not cause damage to the cells of the upper respiratory tract but rather cause changes in the tight junctions of epithelial cells. This allows the virus to gain access to tissues under the epithelial cells and initiate the innate and adaptive immune responses.

Scientists at Ghent University Hospital (Ghent, Belgium) and their colleagues used a collection of quality control samples (QCMD) and clinical samples previously analyzed with validated routine methods. A collection of 111 samples, 43 QCMD samples, 13 bronchoalveolar lavage fluids and 55 nasopharyngeal aspirates/swabs, were tested with the Allplex Respiratory Panel Assays.

The clinical samples were tested previously using either FTD Respiratory Pathogens 21 qPCR assay, an in-house multiplex polymerase chain reaction (PCR) for Bordetella, or BioGX Sample-Ready Atypical pneumo panel. Samples were stored at -80 °C prior to analysis with Seegene Allplex, nucleic acids were automatically extracted with NucliSENS Easymag.

The investigators reported that the Seegene Allplex assay correctly identified 41/43 QCMD samples (95.4%); two samples positive for respiratory syncytial virus (RSV) and human metapneumovirus, respectively, were only correctly identified following repeat testing. In the 56 clinical samples, overall, 97 pathogens were identified: 65 pathogens (67.0%) were detected both by routine methods and Seegene, 24 pathogens (24.7%) only by routine methods, and eight pathogens (8.2%) only by Seegene. The majority of discordant results was detected in samples with low pathogen load (22/32, 68.8%) and in samples containing multiple pathogens (25/32, 78.1%). Full agreement between methods was observed for influenza, RSV, adenovirus, Bordetella (para)pertussis and Chlamydia pneumoniae. Discordance was observed for human metapneumovirus, coronavirus OC43, bocavirus and parainfluenza virus, mainly type 4.

The authors concluded that overall, the Seegene Allplex assay performed well for routine detection of important respiratory targets. Acceptable agreement was observed between Seegene and other routine assays. The study was published on October 11, 2018, in the journal Acta Clinica Belgica.

Related Links:
Ghent University Hospital


Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Clinical Informatics Platform
CLARION™
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Graphical abstract (Pandya T, Zagorulya M, Leung MM, et al. Plasma signals of lung tumor promotion for molecular cancer prevention. Cell. 2026. doi:10.1016/j.cell.2026.05.005)

Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead

Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.